News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fibrotech Announces Positive Phase Ia Results For Anti-Fibrotic FT011


3/10/2014 9:19:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MELBOURNE, Australia--(BUSINESS WIRE)--Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg. At the same time Fibrotech announced the commencement of a Phase Ib trial involving patients with diabetic nephropathy associated with Type 1 or Type 2 diabetes. Both trials have been and will be conducted in Australia.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
Fibrotech
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES